Back to Search
Start Over
Discovery of New Transmitter Systems and Hence New Drug Targets.
- Source :
-
Advances in neurobiology [Adv Neurobiol] 2023; Vol. 30, pp. 181-193. - Publication Year :
- 2023
-
Abstract
- The development of medications used to treat psychiatric conditions has largely proceeded through serendipity, where a potential drug to treat mental illness is identified by chance. This approach is based on a limited understanding of the underlying pathophysiology of mental illness and brain disorders. Identification of novel neurotransmitter systems has allowed for new molecular-based approaches for drug development that identify specific receptor targets to treat a specific symptom. An example of this approach includes the development of suvorexant, which is a dual orexin receptor antagonist FDA approved in 2014 for the treatment of insomnia. This chapter will discuss challenges in psychiatric drug development; the importance of identifying discrete neurotransmitter systems that target a specific symptom, not a syndrome; the orexin pathway and targets within this pathway that can be used to modulate sleep; and a high-throughput approach to streamlining drug development.<br /> (© 2023. The Author(s), under exclusive license to Springer Nature Switzerland AG.)
Details
- Language :
- English
- ISSN :
- 2190-5215
- Volume :
- 30
- Database :
- MEDLINE
- Journal :
- Advances in neurobiology
- Publication Type :
- Academic Journal
- Accession number :
- 36928850
- Full Text :
- https://doi.org/10.1007/978-3-031-21054-9_7